{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T05:10:25Z","timestamp":1659157825676},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T00:00:00Z","timestamp":1455667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T00:00:00Z","timestamp":1455667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s12072-015-9699-9","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T04:35:14Z","timestamp":1455683714000},"page":"478-487","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis"],"prefix":"10.1007","volume":"10","author":[{"given":"Edward J.","family":"Gane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gine","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Stedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlodzimierz","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viera","family":"Kupcova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Le Pogam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Morcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Scalori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Thommes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,17]]},"reference":[{"key":"9699_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195\u20131206","journal-title":"N Engl J Med"},{"key":"9699_CR2","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405\u20132416","journal-title":"N Engl J Med"},{"key":"9699_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207\u20131217","journal-title":"N Engl J Med"},{"key":"9699_CR4","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417\u20132428","journal-title":"N Engl J Med"},{"key":"9699_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2012.11.020","volume":"58","author":"S Bruno","year":"2013","unstructured":"Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis\/cirrhosis. J Hepatol 2013;58:479\u2013487","journal-title":"J Hepatol"},{"key":"9699_CR6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433\u20131444","journal-title":"Hepatology"},{"key":"9699_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","volume":"147","author":"C H\u00e9zode","year":"2014","unstructured":"H\u00e9zode C, Fontaine H, Dorival C, Zoulim F, Larrey D, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132\u2013142","journal-title":"Gastroenterology"},{"key":"9699_CR8","unstructured":"FDA Antiviral Drugs Advisory Committee Meeting. October 24, 2013. Background package for NDA205123. Simeprevir (TMC435); 2013"},{"key":"9699_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1053\/j.gastro.2013.06.051","volume":"145","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013;145:790\u2013800","journal-title":"Gastroenterology"},{"key":"9699_CR10","doi-asserted-by":"crossref","unstructured":"Everson G, Cooper C, Hezode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, et al. DAUPHINE: a randomized phase II study of danoprevir\/ritonavir plus peginterferon alpha-2a\/ribavirin in HCV genotypes 1 or 4. Liver Int 2014 Jan 19","DOI":"10.1111\/liv.12471"},{"key":"9699_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467\u20131475","journal-title":"Lancet"},{"key":"9699_CR12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jhep.2011.01.046","volume":"55","author":"EJ Gane","year":"2011","unstructured":"Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir\/ritonavir plus PEG-IFN alpha-2a\/RBV in hepatitis C patients. J Hepatol 2011;55:972\u2013979","journal-title":"J Hepatol"},{"issue":"Suppl","key":"9699_CR13","first-page":"231-2A","volume":"56","author":"JJ Feld","year":"2012","unstructured":"Feld JJ, Jacobson IR, Jensen DM, Foster G, Pol S, Tam E, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R)\u00a0\u00b1\u00a0peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract 81]. Hepatology 2012;56(Suppl.):231-2A","journal-title":"Hepatology"},{"issue":"Suppl","key":"9699_CR14","first-page":"741A","volume":"58","author":"DM Jensen","year":"2013","unstructured":"Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: SVR4 results from the ANNAPURNA study (abstract 1098). Hepatology. 2013;58(Suppl.):741A","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"9699_CR15","doi-asserted-by":"publisher","first-page":"S555","DOI":"10.1016\/S0168-8278(12)61423-8","volume":"56","author":"EJ Gane","year":"2012","unstructured":"Gane EJ, Pockros P, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, et al. Interferon-free treatment with a combination of mericitabine and danoprevir\/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients [abstract 1412]. J Hepatol 2012;56(Suppl. 2):S555\u2013S556","journal-title":"J Hepatol"},{"key":"9699_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/hep.26275","volume":"58","author":"PJ Pockros","year":"2013","unstructured":"Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, et al. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a\/ribavirin for 24\u00a0weeks in treatment-naive HCV genotype 1\/4 patients. Hepatology 2013;58:514\u2013523","journal-title":"Hepatology"},{"key":"9699_CR17","unstructured":"Leveque V, Fung A, Le Pogam S, Kang H, Harris S, Cammack N, et al. Nucleoside analog R7128, a prodrug of PSI-6130, shows inhibition potency across HCV genotypes 1\u20136 in vitro. Poster P-215 presented at the 16th International Symposium on Hepatitis C Virus and Related Viruses. 3\u20137 October, 2009"},{"key":"9699_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3851\/IMP2088","volume":"17","author":"JM Pawlotsky","year":"2012","unstructured":"Pawlotsky JM, Najera I, Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 2012;17:411\u2013423","journal-title":"Antivir Ther"},{"key":"9699_CR19","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1086\/656774","volume":"202","author":"S Le Pogam","year":"2010","unstructured":"Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010;202:1510\u20131519","journal-title":"J Infect Dis"},{"key":"9699_CR20","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40262-013-0077-2","volume":"52","author":"BJ Brennan","year":"2013","unstructured":"Brennan BJ, Moreira SA, Morcos PN, Navarro MT, Asthappan J, Goelzer P, et al. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin. Clin Pharmacokinet 2013;52:805\u2013813","journal-title":"Clin Pharmacokinet"},{"key":"9699_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2133\/dmpk.DMPK-13-RG-016","volume":"29","author":"C Washington","year":"2014","unstructured":"Washington C, Moreira S, Haznedar J, Goelzer P, Chen YC. Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects. Drug Metab Pharmacokinet. 2014;29:141\u2013147","journal-title":"Drug Metab Pharmacokinet"},{"key":"9699_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.01598-08","volume":"53","author":"MF McCown","year":"2009","unstructured":"McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009;53:2129\u20132132","journal-title":"Antimicrob Agents Chemother"},{"key":"9699_CR23","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. http:\/\/www.hcvguidelines.org. Accessed 30 Jan 2014; 2014"},{"key":"9699_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211\u2013221","journal-title":"N Engl J Med"},{"key":"9699_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515\u2013523","journal-title":"Lancet"},{"issue":"Suppl","key":"9699_CR26","first-page":"1379-80A","volume":"58","author":"IM Jacobson","year":"2013","unstructured":"Jacobson IM, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study (abstract). Hepatology 2013;58(Suppl):1379-80A","journal-title":"Hepatology"},{"issue":"Suppl","key":"9699_CR27","first-page":"1288A","volume":"58","author":"H Razavi","year":"2013","unstructured":"Razavi H, Hindman S, Gower E, Estes C. Global distribution of HCV genotypes. Hepatology 2013;58(Suppl):1288A","journal-title":"Hepatology"},{"key":"9699_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/clpt.2013.203","volume":"95","author":"AJ Muir","year":"2014","unstructured":"Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, Klein TE, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens. Clin Pharmacol Ther 2014;95:141\u2013146","journal-title":"Clin Pharmacol Ther"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-015-9699-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9699-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:17:44Z","timestamp":1659097064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-015-9699-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,17]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["9699"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9699-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,17]]},"assertion":[{"value":"3 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"E. J. Gane\u2014advisory boards for Gilead, AbbVie, Idenix, Achillion, Novartis, Janssen and Roche; R. Rouzier\u2014None to declare; T. Hassanein\u2014Research Grants: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Gilead Sciences, Janssen, Idenix, Ikaria, Mochida, Roche, Ocera, Taigen, Takeda, Salix, Sundise, Vertex. Speaker: Baxter, Bristol-Myers Squibb, Gilead, Salix; Advisory Board: AbbVie, Bristol-Myers Squibb; C. A. Stedman\u2014advisory boards for Roche, MSD, Gilead Sciences and Janssen; W. Mazur\u2014has received lecture fees from Gilead, Roche, Bristol-Myers Squibb, Janssen, and AbbVie; consulting fees from MSD, Gilead, Roche, Bristol-Myers Squibb and Abbott; has participated as an investigator in clinical trials for GlaxoSmithKline, Roche, Gilead, Janssen, AbbVie, and Bristol-Myers Squibb; V. Kupcova\u2014None to declare; S. Le Pogam\u2014Hoffmann La Roche employee at the time of the study; S. Eng\u2014Genentech\/Roche employee at the time of the study; A. Voulgari\u2014Employee of Roche; P. Morcos\u2014Employee of Roche; B. J. Brennan\u2014Employee of Roche; A. Scalori\u2014Employee of Roche; J. Thommes\u2014Employee of Genentech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was attained et al. sites prior to patient recruitment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The study was conducted in accordance with the principles of the Declaration of Helsinki and amendments and in compliance with Guidelines for Good Clinical Practice and EU Directive 2001\/20\/EC. The protocol was approved by the research ethics committee at each participating centre and each patient provided written informed consent before undergoing any study procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}